Guardian Pharmacy Services Stock Alpha and Beta Analysis
| GRDN Stock | 36.27 -0.31 -0.85% |
Investors monitoring Guardian Pharmacy Services can use this module to assess both alpha and beta simultaneously. This decomposition supports assessment of whether Guardian Pharmacy's return profile justifies its risk level. The module provides tools to evaluate risk-adjusted return across custom time periods for Guardian Pharmacy Services. Monitoring these metrics over time reveals the evolving risk-return dynamics of Guardian Pharmacy. A set of indicators related to Guardian Pharmacy's risk premium analysis is presented below. Multi-period comparison reveals whether alpha and beta are stable or regime-dependent for Guardian Pharmacy.
Beta 0.85 | Alpha 0.18 | Risk 2.45 | Sharpe Ratio 0.06 | Expected Return 0.14 |
Beta above 1 implies an asset amplifies market moves; below 1 suggests lower sensitivity. High beta without positive alpha means the investment took more risk without superior returns. Beta represents compensation for unavoidable systematic risk embedded in the broader market. The alpha-beta framework remains one of the most widely used tools in investment analysis.
Guardian |
Market Premiums
Market premium analysis for Guardian Pharmacy Services frames the extra return investors may expect for taking on broad market risk. Combining market premium with volatility, diversification, and the investor's actual time horizon produces a more grounded assessment.| α | 0.18 | β | 0.85 |
Expected Buy-and-Hold Returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Guardian Pharmacy's Buy-and-hold return. Our buy-and-hold chart shows how Guardian Pharmacy performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Market Price Analysis
Studying market price indicators for Guardian Pharmacy Services clarifies whether current moves are reinforcing the thesis or signaling a weaker trading setup. Enterprise value (TTM) is near 2.38 billion and annual revenue is around 1.45 billion. Applied to recent data, these indicators refine entry and exit timing instead of reacting only to headline moves.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Balance Of Power | ||
| Triple Exponential Moving Average | ||
| Parabolic SAR | ||
| Belt hold | ||
| Hanging Man |
Return and Market Media
The median price of Guardian Pharmacy for the period between Fri, Feb 6, 2026 and Thu, May 7, 2026 is 35.62 with a coefficient of variation of 6.41. The daily time series for the period is distributed with a sample standard deviation of 2.28, arithmetic mean of 35.56, and mean deviation of 2.05. The Stock did not receive any noticeable media coverage during the period. Price Growth (%) |
| Timeline |
Performance Metrics & Calculation Methodology
Guardian Pharmacy risk-adjusted performance measures whether returns compensate for the volatility borne by holders. Sharpe and Sortino ratios frame return efficiency relative to total and downside risk. Guardian Pharmacy shows ROE of 26.62%, ROA of 13.68% (TTM).
Guardian Pharmacy Services metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Return and risk statistics are calculated from historical price series.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
Tracking market mood for Guardian Pharmacy adds a behavior lens on top of core and technical work. How strong the bullish or bearish mood on Guardian Pharmacy is matters as much as its direction. When Guardian Pharmacy's mood and price trend split, it is a classic flag for a possible reversal. Common mood-based approaches to Guardian Pharmacy combine many signals for cross-checking.
Build Portfolio with Guardian Pharmacy
Optimization tools reveal whether capital allocated to Guardian Pharmacy Services is being used efficiently relative to other opportunities in the same equity universe. When applied, optimization turns position sizing and rebalancing into measurable decisions rather than guesswork.